InvestorsHub Logo
Followers 22
Posts 888
Boards Moderated 0
Alias Born 05/09/2012

Re: JUST 10-11-12 post# 50788

Thursday, 01/09/2014 1:03:52 PM

Thursday, January 09, 2014 1:03:52 PM

Post# of 403091
I think you are missing my point. I am suggesting that Amgen may believe that their patent covers Kevetrin and thus belongs to them, meaning Cellceutix maybe not be able to profit from Kevetrin. The patent seems to have been approved very quickly for whatever it was. Hope this isn't setting up a legal dispute.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News